

Special Report

Longevity Economy: Investing in an Aging World



Executive summary: Longevity is reshaping the global economy as populations age at an unprecedented rate

Market Context & Summary

- The number of people aged **80** or above will nearly **triple by 2050**, reaching an estimated **426 million**, highlighting the growing longevity segment.
- **Life expectancy** has increased by roughly **20 years** since the 1960s due to advances in healthcare, nutrition, and living standards. For example, current life expectancy in developed countries is over 80 years, and ongoing improvements are extending healthy lifespans.
- The aging demographic shift is no longer limited to high-income countries; by 2050, around **two-third** of the global population aged **60 and above** will reside in **low- and middle-income countries**.
- **Women** represent a larger share of the older population, accounting for about **55%** of those aged 60 and above; this percentage grows with age, reflecting a longer life expectancy.
- This demographic change is driving an economic phenomenon called the “**longevity economy**,” which is expected to reach a market size of approximately **\$8 trillion** by 2030, reflecting the growing spending power and service needs of older consumers across sectors.


Growing Share of Older Adults



By 2030, around **1 in 6** people globally will be aged 60 or above, reflecting rapid demographic aging. This shift highlights the growing economic and social influence of the older population worldwide.

Global Aging Population Growth Chart


Figures in billion



By 2050, the global population aged 60 and above is projected to double to **~2.1 billion**, making up **~26%** of the world population.

Source: UBS, WHO, Aranca Research


Investment horizons: Aging trends are unlocking new opportunities across sectors



Source: PitchBook, UBS, Aranca Research

Market trends: Investments Remain Active Despite Volatile Deal Flow

VC Deal Activity in Longevity Tech



Company	Total Raised (\$ Million)	Last Financing Deal Type	Year Founded
Altos Lab	\$5,565.0	PE Growth/Expansion	2021
Human Longevity	\$1,087.8	Later-Stage VC	2013
InSilico Medicine	\$536.3	Later-Stage VC	2014
Unity Biotechnology	\$355.3	Public Investment	2009
Juvenescence	\$231.7	Later-Stage VC	2017

Source: PitchBook, All data as on 31st March 2025. Geography: Global

Venture Capital, Private Equity, and Market Leaders Shaping the Aging Economy

~\$8.2 billion invested in longevity research between 2020–24, spanning **216 investments** in biotech, digital health, and consumer sectors.

VC remains the primary funding source, contributing about **67%** of early-stage investment in anti-aging biotech, AI health platforms, and wellness solutions.

High-profile backers like **Jeff Bezos, Sam Altman**, and **Brian Armstrong** are fueling breakthroughs in anti-aging and cell therapy.

Major PE/VC deals, such as **KKR–Bright Spring, Humana–Kindred**, and **Longevity Fund** biotech IPOs, reflect strong market optimism.

Public market leaders such as **AbbVie, Amgen, Welltower, Dexcom**, and **Humana** are expanding R&D and acquisitions in age-related solutions.

Source: PitchBook, SSRN, Yahoo Finance, Forbes, Aranca Research

Outlook and risks: Transformative growth ahead, but scientific and regulatory challenges remain critical



Opportunities

Growing public and private funding continues to support the development of new therapies and transformative digital health solutions.

Institutional interest in longevity is accelerating, making the sector a mainstream investment theme.

The crossover between healthcare, technology, and consumer markets fuels rapid innovation and expansion.

Emerging business models emphasize preventive care and personalization for sustainable growth.



Challenges

The science of aging remains highly complex, with many unknowns in biological mechanisms and therapeutic effectiveness.

Regulatory pathways for novel anti-aging treatments are slow to evolve and remain uncertain across major markets.

The high cost of research, clinical development, and commercialization creates barriers to scalability in the near term.

Market volatility, IPO risks, and frequent scientific setbacks can undermine investor confidence and slow capital inflows.



2500+

Global Clients

500+

Strong professional team across
multi-disciplinary domains

120+

Sectors and sub-sectors
researched by our analysis

80+

Countries where we have
delivered projects

ABOUT ARANCA



Growth Advisory & Procurement

CXOs in Strategy, SBUs, Sales, Marketing, CI/MI, Innovation



Valuation & Financial Advisory

CFOs in Start-ups, PE/VC Firms, Corporate M&A Teams, Mid-market Companies



Technology | IP Research & Advisory

R&D, Tech Scouting, Open Innovation, IP Teams, Product Development



Investment Research & Analytics

Brokerage, Hedge Funds, IRPs, I-Banks, AMCs, Investor Relations

For more details: www.aranca.com | <https://www.linkedin.com/company/aranca> | <https://www.aranca.com/knowledge-library>

Connect with our Team



Shantanu Behere

Analyst,
Investment Research

+91 223937 9999
shantanu.behere@aranca.com



Manan Kumar

Manager,
Investment Research

+91 124668 9999
manan.kumar@aranca.com



Akash Khairnar

Associate Vice President,
Investment Research

+91 223937 9999
akash.khairnar@aranca.com



Avinash Singh

Head,
Investment Research

+91 124668 9999 (ext. 951)
avinashg.singh@aranca.com

For more details: www.aranca.com | <https://www.linkedin.com/company/aranca> | <https://www.aranca.com/knowledge-library>

Decide Fearlessly

From startups to the Fortune 500, private equity and global financial firms, Aranca is the trusted research and advisory partner for over 2500 companies

www.aranca.com



This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission.
All rights reserved.